- Home
- GPCR vs ATUS Comparison
GPCR vs ATUS Comparison
Compare GPCR & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- ATUS
- Stock Information
- Founded
- GPCR 2016
- ATUS 2015
- Country
- GPCR United States
- ATUS United States
- Employees
- GPCR N/A
- ATUS N/A
- Industry
- GPCR
- ATUS Cable & Other Pay Television Services
- Sector
- GPCR
- ATUS Telecommunications
- Exchange
- GPCR Nasdaq
- ATUS Nasdaq
- Market Cap
- GPCR 1.1B
- ATUS 935.4M
- IPO Year
- GPCR 2023
- ATUS 2017
- Fundamental
- Price
- GPCR $21.08
- ATUS $2.12
- Analyst Decision
- GPCR Strong Buy
- ATUS Buy
- Analyst Count
- GPCR 7
- ATUS 7
- Target Price
- GPCR $76.17
- ATUS $2.75
- AVG Volume (30 Days)
- GPCR 844.3K
- ATUS 4.6M
- Earning Date
- GPCR 08-07-2025
- ATUS 08-07-2025
- Dividend Yield
- GPCR N/A
- ATUS N/A
- EPS Growth
- GPCR N/A
- ATUS N/A
- EPS
- GPCR N/A
- ATUS N/A
- Revenue
- GPCR N/A
- ATUS $8,855,764,000.00
- Revenue This Year
- GPCR N/A
- ATUS N/A
- Revenue Next Year
- GPCR N/A
- ATUS N/A
- P/E Ratio
- GPCR N/A
- ATUS N/A
- Revenue Growth
- GPCR N/A
- ATUS N/A
- 52 Week Low
- GPCR $13.22
- ATUS $1.52
- 52 Week High
- GPCR $47.48
- ATUS $3.20
- Technical
- Relative Strength Index (RSI)
- GPCR 42.73
- ATUS 46.76
- Support Level
- GPCR $20.91
- ATUS $1.96
- Resistance Level
- GPCR $23.67
- ATUS $2.20
- Average True Range (ATR)
- GPCR 1.46
- ATUS 0.11
- MACD
- GPCR 0.04
- ATUS 0.01
- Stochastic Oscillator
- GPCR 21.43
- ATUS 44.32
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About ATUS Altice USA Inc.
Altice Europe acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and business in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.